Table 2.
Clinicopathologic variables in neuroendocrine tumour liver metastases
| All | |
|---|---|
| Age, years | |
| Median | 53 |
| Range | 25–84 |
| Tumour size, cm | |
| Median | 8.5 |
| Range | 1.0–22.3 |
| Tumour number | |
| Median | 2 |
| Range | 1–11 |
| Gender | |
| Male | 13 (33%) |
| Female | 26 (67%) |
| Margin | |
| R0 | 11 (28%) |
| R1 | 11 (28%) |
| R2 | 15 (39%) |
| Grade | |
| Low | 19 (49%) |
| Intermediate | 13 (33%) |
| High | 7 (18%) |
| Primary site | |
| Pancreas | 11 (28%) |
| Small bowel | 8 (21%) |
| Unknown | 14 (36%) |
| Other | 6 (15%) |
| Symptoms | |
| Present | 28 (72%) |
| Octreotide therapy | |
| Yes | 11 (28%) |
| Chemotherapy | |
| Yes | 10 (26%) |
| Embolization | |
| Yes | 15 (39%) |
| CD3 | |
| High (2–3) | 23 (59%) |
| Low (0–1) | 16 (41%) |
| CD4 | |
| High (3) | 21 (54%) |
| Low (0–2) | 18 (46%) |
| CD8 | |
| High (2–3) | 22 (56%) |
| Low (0–1) | 17 (44%) |
| FoxP3 | |
| High (1–3) | 13 (33%) |
| Low (0) | 26 (67%) |